Table 4.
Antiretroviral Therapy Drugs Detected in Serum of HOPE Donors by Mass Spectrometry
| No. With Drug Detected in Serum/Total No. | ||
|---|---|---|
| Individual ART Drug | All Donorsa | Donors With HIV VL <400 Copies/mLb (n = 23) |
| NRTIs | ||
| 3TC | 7/8 | 6/6 |
| ABC | 2/6 | 1/5 |
| d4T | 0/1 | 0/1 |
| FTC | 15/26 | 11/17 |
| TAF | 1/20 | 1/14 |
| TDF | 3/6 | 2/3 |
| NNRTIsc | ||
| RPV | 0/2 | 0/2 |
| PIsc | ||
| ATV | 3/3 | 2/2 |
| DRV | 5/5 | 4/4 |
| RTV | 3/4 | 2/2 |
| INSTIsc | ||
| EVG | 6/10 | 4/5 |
| DTG | 9/11 | 8/9 |
Abbreviations: 3TC, lamivudine; ABC, abacavir; ART, antiretroviral therapy; ATV, atazanavir; d4t, stavudine; DRV, darunavir; DTG, dolutegravir; EVG, elvitegravir; FTC, emtricitabine; HIV, human immunodeficiency virus; HOPE, HIV Organ Policy Equity; INSTIs, integrase strand transfer inhibitors; NNRTIs, nonnucleoside reverse-transcriptase inhibitors; NRTIs, nucleoside reverse-transcriptase inhibitors; PIs, protease inhibitors; RPV, rilpivirine; RTV, ritonavir; TAF, tenofovir alafenamide; TDF, tenofovir disoproxil fumarate; VL, viral load.
aMass spectrometric data were unavailable for 3 of 37 donors with reported ART use, whose drug regimens are excluded from this table: ABC/3TC/DTG, TAF/FTC/RPV, and TAF/FTC/bictegravir (1 donor each)
bHIV VLs were available for 33 of 34 donors with mass spectrometric data and known ART regimens, including 23 with VLs <400 copies/mL.
cBictegravir, etravirine, and cobicistat were not assayed by mass spectrometry.